Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

33.12B

Market cap33.12B

Price-Earnings ratio

-140.99

Price-Earnings ratio-140.99

Dividend yield

—

Dividend yield—

Average volume

1.26M

Average volume1.26M

High today

$237.15

High today$237.15

Low today

$228.11

Low today$228.11

Open price

$231.56

Open price$231.56

Volume

2.48M

Volume2.48M

52 Week high

$256.36

52 Week high$256.36

52 Week low

$131.81

52 Week low$131.81

Stock Snapshot

The current Natera(NTRA) stock price is $231.41, with a market capitalization of 33.12B. The stock trades at a price-to-earnings (P/E) ratio of -140.99.

On 2026-06-20, Natera(NTRA) stock traded between a low of $228.11 and a high of $237.15. Shares are currently priced at $231.41, which is +1.4% above the low and -2.4% below the high.

Natera(NTRA) shares are trading with a volume of 2.48M, against a daily average of 1.26M.

In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $131.81.

NTRA News

Simply Wall St 47m

Natera Stock Could Be 11.3% Undervalued After Prospera Transplant Data

Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when...

Simply Wall St 3d

Is Natera’s CytoDyn ctDNA Tie-Up and Board Refresh Reframing the Investment Case for NTRA?

Natera, Inc. recently announced a collaboration with CytoDyn to use its Signatera assay and oncology real-world data to analyze circulating tumor DNA and molecu...

Investing.com 3d

Natera executive chairman sells $21.4 million in shares - Investing.com

...

Analyst ratings

86%

of 22 ratings

Buy

86.4%

Hold

13.6%

Sell

More NTRA News

TipRanks 3d

Natera Shareholders Approve Equity Plan and Governance Proposals

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Flowserve

Modine

iShares MSCI Emerging Mar…

CSX

Linde plc

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.